BIOLQ (Biolase) Debt-to-Equity: -3.58 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOLQ Biolase Inc BIOLQ
16 GF Score
Price $0.00
View Full Analysis

What is Biolase Debt-to-Equity?

Biolase BIOLQ -99.00% 16 Debt-to-Equity is -3.58 as of Sep. 2024. GuruFocus rates BIOLQ with a GF Score™ of 16/100.

Biolase's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $18.48 Mil. Biolase's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.21 Mil. Biolase's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-5.23 Mil. Biolase's debt to equity for the quarter that ended in Sep. 2024 was -3.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biolase's Debt-to-Equity or its related term are showing as below:

BIOLQ's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.24
* Ranked among companies with meaningful Debt-to-Equity only.

Biolase  (OTCPK:BIOLQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biolase Debt-to-Equity Related Terms

Biolase Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Biolase's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase Debt-to-Equity Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.59 1.82 0.61 3.21 -63.59

Biolase Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.13 -63.59 -7.99 -3.38 -3.58

BIOLQ vs OPGN, AFIB, ABT: Debt-to-Equity Comparison

For the Medical Devices subindustry, Biolase's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolase Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biolase's Debt-to-Equity falls into.


BIOLQ
16GF Score
Biolase Inc BIOLQ
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biolase Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biolase's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.153 + 12.554) / -0.247
=-63.59

Biolase's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(18.479 + 0.211) / -5.227
=-3.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -3.58 mean?
Biolase (BIOLQ) has a Debt-to-Equity of -3.58 as of Sep. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biolase and its competitors.
Is Biolase's Debt-to-Equity too high?
Biolase's current Debt-to-Equity is -3.58. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biolase's Debt-to-Equity compare to OPGN and AFIB?
Biolase's Debt-to-Equity of -3.58 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biolase and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biolase's current Debt-to-Equity is -3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biolase stock overvalued right now?
Biolase (BIOLQ) has a current Debt-to-Equity of -3.58. The current Debt-to-Equity is -3.58. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Biolase (BIOLQ), the current Debt-to-Equity is -3.58 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biolase Business Description

Address 27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
16GF Score

Get the complete analysis for BIOLQ

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price